Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China Issues Fast-Track Registration For Drugs To Balance Innovation And Risk

This article was originally published in The Pink Sheet Daily

Executive Summary

Drugs and APIs in four categories now can gain approval in 120 days, down from 150.

You may also be interested in...



AstraZeneca Healthcare Policy Research VP James Cai On Building A CRO Community In China: An Interview With PharmAsia News

James Cai, AstraZeneca's VP, Healthcare Policy Research, sat down with PharmAsia News' Shanghai bureau during the China Trials 2008 conference in November to discuss the burgeoning CRO landscape in China and how multinational companies can work with local CROs to improve the clinical trial infrastructure there.

SFDA Drafts New Fast Track Procedures For Drug Registration

SHANGHAI - China regulators released a streamlined draft drug approval rule this month that would provide for faster approval of four categories of new drugs. The State Food and Drug Administration finished collecting public comments on the rule Oct. 15

Asia Spotlight: China's Top Drug Distributors Are Soaring

On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.

Topics

Latest News
UsernamePublicRestriction

Register

PS068460

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel